The Effect of Doxazosin, Finasteride and Combination Therapy on Nocturia in Men With Benign Prostatic Hyperplasia

Theodore M. Johnson, Pamela K. Burrows, John W. Kusek, Leroy M. Nyberg, J. Lisa Tenover, Herbert Lepor, Claus Roehrborn

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Purpose: We evaluated the effectiveness of single or combination drug therapy on nocturia in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Materials and Methods: A total of 3,047 men with lower urinary tract symptoms/benign prostatic hyperplasia enrolled in the Medical Therapy of Prostatic Symptoms trial were randomly assigned to receive doxazosin alone, finasteride alone, combination therapy or placebo. Treatment effectiveness was assessed according to intent to treat by mean reduction in self-reported nightly nocturia at 1 and 4 years. A subgroup analysis by age (younger than 70 vs 70 years old or older) was also performed. Results: Of the men 2,583 reported 1 or more episodes of nocturia and finished 12 or more months of the trial. Mean nocturia was similar in all groups at baseline. Mean nocturia was reduced at 1 year by 0.35, 0.40, 0.54 and 0.58 in the placebo, finasteride, doxazosin and combination groups, respectively. Reductions with doxazosin and combination therapy were statistically greater than with placebo (p <0.05). At 4 years nocturia was also significantly reduced in patients treated with doxazosin and combination therapy (p <0.05 vs placebo). In men older than 70 years (495) all drugs significantly reduced nocturia at 1 year (finasteride 0.29, doxazosin 0.46 and combination 0.42) compared to placebo (0.11, p <0.05). Conclusions: Doxazosin and combination therapy reduced nocturia more than placebo, but the net benefit of active drug compared to placebo was often modest with a net difference of less than 0.20 fewer nightly nocturia episodes at 1 and 4 years. Findings in men 70 years old or older were similar, with an even smaller effect observed for finasteride.

Original languageEnglish (US)
Pages (from-to)2045-2051
Number of pages7
JournalJournal of Urology
Volume178
Issue number5
DOIs
StatePublished - Nov 2007

Fingerprint

Doxazosin
Finasteride
Nocturia
Prostatic Hyperplasia
Placebos
Lower Urinary Tract Symptoms
Therapeutics
Combination Drug Therapy
Pharmaceutical Preparations

Keywords

  • adrenergic alpha-antagonists
  • finasteride
  • nocturia
  • prostatic hyperplasia

ASJC Scopus subject areas

  • Urology

Cite this

The Effect of Doxazosin, Finasteride and Combination Therapy on Nocturia in Men With Benign Prostatic Hyperplasia. / Johnson, Theodore M.; Burrows, Pamela K.; Kusek, John W.; Nyberg, Leroy M.; Tenover, J. Lisa; Lepor, Herbert; Roehrborn, Claus.

In: Journal of Urology, Vol. 178, No. 5, 11.2007, p. 2045-2051.

Research output: Contribution to journalArticle

Johnson, Theodore M. ; Burrows, Pamela K. ; Kusek, John W. ; Nyberg, Leroy M. ; Tenover, J. Lisa ; Lepor, Herbert ; Roehrborn, Claus. / The Effect of Doxazosin, Finasteride and Combination Therapy on Nocturia in Men With Benign Prostatic Hyperplasia. In: Journal of Urology. 2007 ; Vol. 178, No. 5. pp. 2045-2051.
@article{a84fa8b75fe74aa29187c7356ff32db9,
title = "The Effect of Doxazosin, Finasteride and Combination Therapy on Nocturia in Men With Benign Prostatic Hyperplasia",
abstract = "Purpose: We evaluated the effectiveness of single or combination drug therapy on nocturia in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Materials and Methods: A total of 3,047 men with lower urinary tract symptoms/benign prostatic hyperplasia enrolled in the Medical Therapy of Prostatic Symptoms trial were randomly assigned to receive doxazosin alone, finasteride alone, combination therapy or placebo. Treatment effectiveness was assessed according to intent to treat by mean reduction in self-reported nightly nocturia at 1 and 4 years. A subgroup analysis by age (younger than 70 vs 70 years old or older) was also performed. Results: Of the men 2,583 reported 1 or more episodes of nocturia and finished 12 or more months of the trial. Mean nocturia was similar in all groups at baseline. Mean nocturia was reduced at 1 year by 0.35, 0.40, 0.54 and 0.58 in the placebo, finasteride, doxazosin and combination groups, respectively. Reductions with doxazosin and combination therapy were statistically greater than with placebo (p <0.05). At 4 years nocturia was also significantly reduced in patients treated with doxazosin and combination therapy (p <0.05 vs placebo). In men older than 70 years (495) all drugs significantly reduced nocturia at 1 year (finasteride 0.29, doxazosin 0.46 and combination 0.42) compared to placebo (0.11, p <0.05). Conclusions: Doxazosin and combination therapy reduced nocturia more than placebo, but the net benefit of active drug compared to placebo was often modest with a net difference of less than 0.20 fewer nightly nocturia episodes at 1 and 4 years. Findings in men 70 years old or older were similar, with an even smaller effect observed for finasteride.",
keywords = "adrenergic alpha-antagonists, finasteride, nocturia, prostatic hyperplasia",
author = "Johnson, {Theodore M.} and Burrows, {Pamela K.} and Kusek, {John W.} and Nyberg, {Leroy M.} and Tenover, {J. Lisa} and Herbert Lepor and Claus Roehrborn",
year = "2007",
month = "11",
doi = "10.1016/j.juro.2007.07.013",
language = "English (US)",
volume = "178",
pages = "2045--2051",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - The Effect of Doxazosin, Finasteride and Combination Therapy on Nocturia in Men With Benign Prostatic Hyperplasia

AU - Johnson, Theodore M.

AU - Burrows, Pamela K.

AU - Kusek, John W.

AU - Nyberg, Leroy M.

AU - Tenover, J. Lisa

AU - Lepor, Herbert

AU - Roehrborn, Claus

PY - 2007/11

Y1 - 2007/11

N2 - Purpose: We evaluated the effectiveness of single or combination drug therapy on nocturia in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Materials and Methods: A total of 3,047 men with lower urinary tract symptoms/benign prostatic hyperplasia enrolled in the Medical Therapy of Prostatic Symptoms trial were randomly assigned to receive doxazosin alone, finasteride alone, combination therapy or placebo. Treatment effectiveness was assessed according to intent to treat by mean reduction in self-reported nightly nocturia at 1 and 4 years. A subgroup analysis by age (younger than 70 vs 70 years old or older) was also performed. Results: Of the men 2,583 reported 1 or more episodes of nocturia and finished 12 or more months of the trial. Mean nocturia was similar in all groups at baseline. Mean nocturia was reduced at 1 year by 0.35, 0.40, 0.54 and 0.58 in the placebo, finasteride, doxazosin and combination groups, respectively. Reductions with doxazosin and combination therapy were statistically greater than with placebo (p <0.05). At 4 years nocturia was also significantly reduced in patients treated with doxazosin and combination therapy (p <0.05 vs placebo). In men older than 70 years (495) all drugs significantly reduced nocturia at 1 year (finasteride 0.29, doxazosin 0.46 and combination 0.42) compared to placebo (0.11, p <0.05). Conclusions: Doxazosin and combination therapy reduced nocturia more than placebo, but the net benefit of active drug compared to placebo was often modest with a net difference of less than 0.20 fewer nightly nocturia episodes at 1 and 4 years. Findings in men 70 years old or older were similar, with an even smaller effect observed for finasteride.

AB - Purpose: We evaluated the effectiveness of single or combination drug therapy on nocturia in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Materials and Methods: A total of 3,047 men with lower urinary tract symptoms/benign prostatic hyperplasia enrolled in the Medical Therapy of Prostatic Symptoms trial were randomly assigned to receive doxazosin alone, finasteride alone, combination therapy or placebo. Treatment effectiveness was assessed according to intent to treat by mean reduction in self-reported nightly nocturia at 1 and 4 years. A subgroup analysis by age (younger than 70 vs 70 years old or older) was also performed. Results: Of the men 2,583 reported 1 or more episodes of nocturia and finished 12 or more months of the trial. Mean nocturia was similar in all groups at baseline. Mean nocturia was reduced at 1 year by 0.35, 0.40, 0.54 and 0.58 in the placebo, finasteride, doxazosin and combination groups, respectively. Reductions with doxazosin and combination therapy were statistically greater than with placebo (p <0.05). At 4 years nocturia was also significantly reduced in patients treated with doxazosin and combination therapy (p <0.05 vs placebo). In men older than 70 years (495) all drugs significantly reduced nocturia at 1 year (finasteride 0.29, doxazosin 0.46 and combination 0.42) compared to placebo (0.11, p <0.05). Conclusions: Doxazosin and combination therapy reduced nocturia more than placebo, but the net benefit of active drug compared to placebo was often modest with a net difference of less than 0.20 fewer nightly nocturia episodes at 1 and 4 years. Findings in men 70 years old or older were similar, with an even smaller effect observed for finasteride.

KW - adrenergic alpha-antagonists

KW - finasteride

KW - nocturia

KW - prostatic hyperplasia

UR - http://www.scopus.com/inward/record.url?scp=35148879015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35148879015&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2007.07.013

DO - 10.1016/j.juro.2007.07.013

M3 - Article

C2 - 17869295

AN - SCOPUS:35148879015

VL - 178

SP - 2045

EP - 2051

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -